Abstract: The invention provides a gel-type water absorbent with rich flexibility and elasticity, with less variation in strength of gel during preservation, with low viscosity of sol, with easy processability, having a physical property with extremely less water discharge, and having functions of water absorbency and water solubility. The gel-type water absorbent contains a tamarind seed polysaccharide including 90% or more dietary fiber, 1% or less protein and 1% or less ash; and a water-soluble organic substance including at least one or more of a polyhydric alcohol and water-soluble surfactant.

Abstract: The present invention has an object to provide a gel composition which has an excellent skin whitening effect and shows high storage stability even when ascorbic acid, a salt of ascorbic acid, an ascorbic acid derivative, and a salt of an ascorbic acid derivative is blended, and to provide a pack cosmetic using the gel composition. The gel composition, which comprises the following components (A)-(D): (A) a tamarind seed polysaccharide; (B) a polyhydric alcohol; (C) at least one or more of ascorbic acid, a salt of ascorbic acid, an ascorbic acid derivative, and a salt of an ascorbic acid derivative; and (D) water.

Abstract: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, an implantable device coated with the composition, and a method of treating a disorder are provided.

Abstract: There is described inter alia a medical device having a surface which comprises a coating layer, the coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which anti-coagulant entity is covalently attached to the surface through a linker comprising a thioether.

Abstract: Disclosed is an interventional device for delivery of therapeutic agents from an angioplasty balloon and from a prosthesis such as an intraluminal stent. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to an interventional device having a prosthesis surface that is loaded with a first beneficial agent, and a balloon surface loaded with a second beneficial agent. The invention also relates to a method of loading multiple beneficial agents onto the prosthesis surfaces and the balloon surfaces, and to a method of manufacturing an interventional device for the delivery of a first beneficial agent and a second beneficial agent from separate surfaces.

Abstract: Disclosed herein is a hydrophilic foam. The hydrophilic foam includes a polyurethane matrix having a plurality of cells. The cells are capable of retaining water in an amount of least about 8 grams of water per gram of the hydrophilic foam.

Abstract: Injectable depot compositions are provided that include a polymer matrix having a plurality of bioerodible, biocompatible polymers wherein each polymer of the plurality of polymers has a specified average molecular weight, and the polymer matrix has a broad molecular weight distribution of the plurality of polymers; a solvent having a miscibility in water of less than or equal to 7 wt % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith; and a beneficial agent. The compositions have substantially improved shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.

Abstract: A composition for administration of a beneficial agent, contains a solvent mixture including a hydrophobic solvent and a hydrophilic solvent; a bioerodible polymer; and a beneficial agent. The polymer and the beneficial agent are dissolved. The composition has a low viscosity, allowing for easy injection through standard hypodermic needles.

Abstract: An implantable graft, which may be inserted into a fistula tract to occlude the primary opening of the fistula, is provided. To prevent unintentional displacement of the graft or extrusion of the graft from the fistula of a patient, the graft may be provided with a cap that extends laterally from at least one end of the body of the graft, where the cap may be integral with the body of the graft, attachable to at least one end of the body of the graft, and/or moveable along the body of the graft. The graft may also have a tail that extends from one end of the body of the graft to assist in placement of the graft in a fistula tract. The graft may be an integral unit made of a single material, such as a heterograft material, or may include distinct components made of the same or different materials. Methods for closing a fistula tract are also provided.

Abstract: An edible chew pill jacket receives a pill/tablet or capsule that is to be administered to a pet, animal or human. The edible chew pill jacket includes a flexible top wall, side walls and bottom wall configured to form a chamber appointed to receive a pill. A flexible longitudinal slit is integrated within the top wall for providing access to the chamber for insertion of the pill within the edible chew pill jacket. The edible chew pill jacket is formulated with at least one flavoring to provide a tasty treat appointed to mask the pill's taste. The chew pill jacket substantially encapsulates the pill/tablet appointed to be orally ingested. The chew pill jacket may include medicament therein, nutrients, vitamins, or may simply be provided as a tasty treat to mask the taste of the pill.

Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.

Abstract: The present invention is directed to shelf-stable liquid egg material, methods for making the same, and method of using the same. The present invention is also directed to an animal feed supplement containing a stabilized IgY antibody titer in liquid eggs stored at room temperature for extended periods of time with the use of glycerol and preservatives. The stabilized liquid whole egg or stabilized liquid yolks of the egg containing non-specific or elevated specific IgY titer may be used as animal feed supplements animals to provide passive immunity to these animals. The stabilized nature of the IgY and liquid egg allows for extended shelf life of these liquid products at room temperature.

Abstract: Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based and the delivery method involves administering a vaccine, including an antigen and the adjuvant, to a mucosal surface.

Abstract: A device for providing oral care. The device is formed to have surface features for delivery of medication or other compositions to the mouth, the throat, the gums and the cheeks. Blisters or cavities are formed on a surface of the device to contain and deliver a material, such as mouthwash or medicine, into the various areas of the mouth of the user, and may be formed to provide a time-controlled release of the deliverable material.

Abstract: Dietary compositions and methods for reducing risk of developing hyperthyroidism in a feline are disclosed. The compositions and methods restrict the amount of selenium intake or restrict the amount of selenium and iodine intake in the feline.

Abstract: A composition comprising a physically discrete pet food oral intake composition coated with a physically stable film, the film comprising a component which is a) capable of carrying a beneficial agent to a site in the pet wherein the benefit agent is effective in producing a beneficial effect or b) capable of releasing the benefit agent into the mouth or alimentary canal with the benefit agent traveling to a site in the pet wherein the benefit agent is effective in producing a beneficial effect.

Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Abstract: The present invention concerns a method for coating granules comprising mesalazine, with a coating mixture comprising two polymers, polymer I and polymer II; said polymer I being selected to allow formation of a closing membrane around said granules in the absence of said polymer II, and said polymer II being selected to act as a water-soluble pore former in said coating mixture; wherein a) the amount of polymer I is adjusted to provide a closing membrane in the absence of polymer II, and b) the amount of polymer II in said coating mixture is adjusted to obtain coated granules which exhibit controlled release of mesalazine. The invention further concerns a product obtainable by the coating method.

Abstract: Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.

Abstract: Coatings for medical devices, methods of making the coatings, and methods of using them are described.

Abstract: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.

Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Abstract: The present invention relates to processes for forming particles including drugs in a solution, changing the bulk or surface properties of a drug particle, and/or microencapsulating drug particles, and compositions produced thereby. In some embodiments, the process described utilizes mechanical agitation, more specifically low-frequency sonication, under controlled conditions, which provides mild shear forces during forming and/or precipitation to control the particle growth and mixing properties. Particle size can range from less than about 200 nanometers to greater than about one millimeter, depending on the processing conditions and application.

Abstract: The present invention relates to compositions and methods for treating cancer and, in particular, to composition and methods comprising nanostructures. In one embodiment, the present invention provides a composition comprising a mixture, the mixture comprising at least one nanoparticle and at least one chemotherapeutic.

Abstract: The reverse vesicle composition of the present invention includes (A) a sphingosine represented by formula (I), (B) a C16 to C30 fatty acid, (C) a hydrocarbon oil, (D) an ester oil which is in liquid form at 25° C., and (F) water, wherein the ratio by mass of ingredient (C) to ingredient (D) satisfies the following relationship: 1?(C)/(D)<1000, and the composition contains a surfactant having a molecular weight of 1,000 or less in an amount of 1 mass % or less.

Abstract: Dicalcium phosphate anhydride powder of which at least 50% by weight is of a grain size of between 45 and 150 ?m, a maximum of 50% by weight is of a grain size of <45 ?m and a maximum of 5% by weight is of a grain size >150 ?m and which has a bulk density of between 1000 and 1500 g/l and a specific surface area of <5 m2/g is used for direct tabletting or capsule filling of pharmaceutical preparations.

Abstract: A method for producing a tableting additive, which method comprises providing a spray dried tableting additive in particulate form which particles at leas partially consist of amorphous additive material and at least partially of crystalline additive material; and crystallising the amorphous additive material by subjecting the particles for a short time and under agitation to a temperature between 30 and 100° C. at a relative humidity between 60 and 25%. More in particular, the relationship between relative humidity and temperature is defined by the formula: % relative humidity=218-47*Ln(T(° C.)), wherein T(° C.) is the temperature to which the particles are subjected.

Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract: The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject.

Abstract: The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof.

Abstract: Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy.

Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.

Abstract: Implementation is directed to selectively inhibiting estrogen production and providing estrogenic effects in a human body. A dietary supplement includes a processed Morinda citrifolia product that is used to inhibit aromatase or aromatase enzymes that function to convert androgens to estrogens, inhibit receptors from binding with estrogen, and reduce and/or regulate estrogen production, as well as reduce the amount of estrogen produced within the body and regulating such production. The dietary supplement further provides estrogenic effects. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: The invention relates to a cosmetic composition containing lingonberry extract and its use on skin cosmetology thereof. The present invention has provided a lingonberry extract wherein containing polyphenols components including anthocyanidin, procyanidin, resveratrol, catechin and so on. The present invention also relates to the application of lingonberry extract on skin cosmetology, including without limitation whitening, diminishing visible pigmentation, anti-wrinkle, moisturizing, smoothing and improving skin sensitivity. The invention also has revealed drugs, cosmetic composition and food prepared by using lingonberry extract. Comparing with the prior art cosmetic compositions, the said lingonberry extract of the present invention has higher effects and safe.

Abstract: Embodiments of the invention relate to a composition for controlling a target pest, wherein the composition includes at least two active ingredients selected from the group consisting of thymyl acetate, linalyl acetate, amyl butyrate, anise star oil, black seed oil, p-cymene, geraniol, isopropyl myristate, d-limonene, linalool, lilac flower oil, methyl salicylate, alpha-pinene, piperonal, piperonyl alcohol, tetrahydrolinalool, thyme oil white, thyme oil red, thymol, vanillin, and winter-green oil, wherein the composition causes synergistic control of the target pest.

Abstract: A botanical composition made from a plurality of plant materials selected from Gota Kola (Centella asiatica), Turmeric Root (Curcuma longa), White Willow (Salix alba), Rosehips (Rosa canina), Hibiscus (Hibiscus sabdariffa), Evening Primrose (Oenothera biennis), and Bilberry (Vaccinium myrtillus), or phytochemicals or extracts or oils derived from the plant materials has beneficial application in addressing retinopathy and recurring peripheral neuropathy. The botanical composition can include a number of additional agents such as antioxidants, benfotiamine, thiamine (vitamin B1), and lipoic acid.

Abstract: The present invention reported that SFE is suitable for Nigella sativa seeds oil extraction and fractionation. TQRF that were produced through SFE extractions (600 bars/40° C.) and fractionations (100-200 bars/40-60° C.) possessed high level of TQ and antioxidant activity. SFE fractionation efficiently concentrates the TQ content and antioxidant activity of Nigella sativa seeds oil in short time and low cost manners without using any hazardous organic solvents.

Abstract: A premix for hog feed and a method of feeding a hog that produces DHA and EPA enriched pork while avoiding or reducing negative effects to the taste, color, texture, aroma, pH and shelf life which are significant enough to make the pork unacceptable to consumers. One embodiment of the method of feeding a hog involves feeding a hog over several days with a hog feed supplemented with the premix. The premix includes marine-sourced docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and plant-sourced alpha-linolenic acid (ALA). The hogs are fed until their total DHA, EPA and ALA intakes are in a certain range per kilogram of the hog's weight. The hogs are then slaughtered and processed into pork products. This results in pork with an enrichment of omega-3 EFAs in the range of about 2.5% to about 4.5% of fat.

Abstract: A method is provided for decalcification of an aqueous solution that has multivalent Ca2+ and Mg2+ cations and anions able to form complexes with at least a part of the multivalent cations. The method includes replacing at least part of the anions to form complexes of the aqueous solution by monovalent anions such as Cl?, non-able to form such complexes. The method also replaces at least a part of the multivalent cations of the aqueous solution by monovalent metal cations such as Na+ and/or K+. This later replacement step is performed simultaneously with or after the first replacement step.

Abstract: Provided herein are salts for use in food products having the formula: MgCl2.xKCl.yNH4Cl.zH2O, wherein x+y is about 1, wherein x is greater than or equal to zero and less than 1, wherein y is greater than zero and less than or equal to 1, and wherein z is from about 4 to about 6.

Abstract: A system and method for preparing a predetermined quantity of beverage suitable for consumption using an extractable product is disclosed. The system comprises at least one disposable capsule; an apparatus comprising a fluid dispensing device for supplying an amount of fluid, such as water, to the at least one disposable capsule, a receptacle for accommodating the at least one disposable capsule, and an outlet arrangement for supplying the beverage to a container, such as a cup. The at least one disposable capsule comprises a chamber for enclosing an inner space comprising the extractable product. The capsule further comprises a displaceable body conceived to interact with an entrance area and an exit area of the capsule for discontinuing the entrance area and the exit area thereby enabling the chamber to pass fluidum there through.

Abstract: The invention pertains to a particulate composition comprising calcium lactate and calcium citrate microparticles having an average diameter from 0.1 ?m to 20 ?m, wherein the composition is in the form of particles with an average diameter from 25 ?m to 1 ?m, wherein the ratio by weight of calcium lactate to calcium citrate, based on the dry weight, is 80:20 to 30:70 , and wherein the calcium lactate is a non-polymeric agglomeration agent for the calcium citrate microparticles. The invention further relates to a process for producing the particulate composition wherein an aqueous solution of calcium lactate comprising calcium citrate microparticles is spray-dried to the particulate composition, to the use of the particulate composition as calcium-enhancer, and to alimentary products.

Abstract: The invention relates to a method for processing cocoa beans wherein freshly harvested, unfermented, and preferably non-depulped, beans are pre-treated and are then immersed a first time within an aqueous acidic medium until the pH of said cocoa beans reaches a value of between 3.6 and 5.5 and incubated at a temperature of between 25 and 70° C. for less than 24 hours. Optionally the beans can then be immersed for a second time within an aqueous acidic medium or the first aqueous acidic medium can be alkalified until the pH of said cocoa beans reaches a value of between 4.5 and 6.5 and incubated at a temperature of between 25 and 70° C. for less than 24 hours. The obtained cocoa beans are then further dried.

Abstract: A pomegranate sprout preparation is disclosed. Methods of producing pomegranate sprouts and pomegranate sprout preparation as well as food or feed products comprising same are also disclosed.

Abstract: The present invention provides a method for preparing storable products that contain most of the nutritious elements contained in milk. Embodiments combine the different milk elements into liquid products of different looks and tastes that can be stored without refrigeration. All of the products could additionally be supplemented with probiotic components that can be activated upon consumption, allowing storage for extended periods of time without refrigeration. Moreover, because they are mainly composed of highly digestible milk protein, these products can be used to encapsulate different therapeutics and vitamin supplements for patients under aggressive therapeutic regimens such as: immunosuppressants, high level antibiotics, chemotherapy. Due to their balance of carbohydrates, protein and lipids, the products can be beneficial for individuals suffering from diabetes or from lactose intolerance. Finally, the products can also work as an effective tool to maintain weight balance.

Abstract: A rack and carts system to hold salmons, trouts and any other kind of similar fish, in a way that a maximum freezing capacity is reached per tunnel (kilos of frozen product per hour) as well as an excellent product presentation.

Abstract: The present invention relates to a method for producing baked goods and a mold apparatus having a cavity in a desired shape for use in said method, the mold apparatus comprising a gap that allows for venting of vapor produced during heating or baking of a mixture in the mold apparatus but does not allow any significant amount of the mixture to escape from the cavity of the mold apparatus via the gaps.

Abstract: The invention provides a process of purifying Rebaudioside C from the Stevia rebaudiana Bertoni plant extract along with Rebaudioside A and Stevioside. The process is useful for producing high purity Rebaudioside C, Stevioside and Rebaudioside A. High purity rebaudioside C is useful as in combination with other caloric and non-caloric sweeteners as well as non caloric sweetener in various food and beverage compositions. The high purity Rebaudioside A and Stevioside are useful as non-caloric sweeteners in edible and chewable compositions such as any beverages, confectioneries, bakeries, cookies, chewing gums, and alike.